For the second time, a study testing an antibody-drug for Covid-19 has been paused to probe a possible safety issue in hospitalized patients. Regeneron said on Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients because of a potential safety problem and unfavorable balance of risks and benefits. Other studies in mild or moderately ill people are continuing. Earlier this month, a different group of monitors recommended pausing enrollment of hospitalized patients in a study testing an Eli Lilly antibody drug.
0 Comments